EGFR-TKIs plus bevacizumab demonstrated survival benefit than EGFR-TKIs alone in patients with EGFR-mutant NSCLC and multiple brain metastases
- PMID: 31569068
- DOI: 10.1016/j.ejca.2019.08.021
EGFR-TKIs plus bevacizumab demonstrated survival benefit than EGFR-TKIs alone in patients with EGFR-mutant NSCLC and multiple brain metastases
Abstract
Introduction: Previous studies suggested that epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKIs) plus bevacizumab could significantly prolong progression-free survival (PFS) than EGFR-TKI alone as first-line setting for patients with EGFR-mutant non-small-cell lung cancer (NSCLC). However, whether this combination could benefit patients with multiple brain metastases (BrMs) remains undetermined.
Methods: A total of 208 patients with EGFR-mutant NSCLC and multiple BrM (number >3, at least one of lesions was measurable) were retrospectively identified. Kaplan-Meier curves with two-sided log-rank tests and Cox proportional hazards model with calculated hazard ratios and 95% confidence intervals were used to determine the survival difference.
Results: Of all patients, 149 patients received EGFR-TKIs monotherapy and 59 received EGFR-TKIs plus bevacizumab as first-line setting. EGFR-TKIs plus bevacizumab was associated with a significantly higher intracranial objective response rate (ORR, 66.1% vs. 41.6%, P = 0.001), systemic ORR (74.6% vs. 57.1%, P = 0.019), longer intracranial PFS (14.0 vs. 8.2 months; P < 0.001) and systemic PFS (14.4 vs. 9.0 months; P < 0.001). Importantly, addition of bevacizumab also had a significantly longer overall survival (OS, 29.6 vs. 21.7 months; P < 0.001). Multivariate analysis consistently revealed that addition of bevacizumab was independently associated with prolonged intracranial and systemic PFS, and OS. No unexpected serious adverse effects were observed.
Conclusions: EGFR-TKIs plus bevacizumab prolonged not only PFS but also OS in patients with EGFR-mutant NSCLC and multiple BrMs when compared with EGFR-TKIs alone, indicating that this combination could be an alternative therapeutic option for those patients.
Keywords: Bevacizumab; Brain metastases; EGFR mutation; Lung cancer.
Copyright © 2019 Elsevier Ltd. All rights reserved.
Similar articles
-
EGFR-TKIs plus chemotherapy demonstrated superior efficacy than EGFR-TKIs alone as first-line setting in advanced NSCLC patients with EGFR mutation and BIM deletion polymorphism.Lung Cancer. 2018 Jun;120:82-87. doi: 10.1016/j.lungcan.2018.04.004. Epub 2018 Apr 4. Lung Cancer. 2018. PMID: 29748021
-
Efficacy of first-line treatment with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) alone or in combination with chemotherapy for advanced non-small cell lung cancer (NSCLC) with low-abundance mutation.Lung Cancer. 2019 Feb;128:6-12. doi: 10.1016/j.lungcan.2018.12.007. Epub 2018 Dec 6. Lung Cancer. 2019. PMID: 30642455
-
EGFR TKIs plus WBRT Demonstrated No Survival Benefit Other Than That of TKIs Alone in Patients with NSCLC and EGFR Mutation and Brain Metastases.J Thorac Oncol. 2016 Oct;11(10):1718-28. doi: 10.1016/j.jtho.2016.05.013. Epub 2016 May 26. J Thorac Oncol. 2016. PMID: 27237825
-
Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis.J Natl Cancer Inst. 2013 May 1;105(9):595-605. doi: 10.1093/jnci/djt072. Epub 2013 Apr 17. J Natl Cancer Inst. 2013. PMID: 23594426 Review.
-
Overview of current systemic management of EGFR-mutant NSCLC.Ann Oncol. 2018 Jan 1;29(suppl_1):i3-i9. doi: 10.1093/annonc/mdx702. Ann Oncol. 2018. PMID: 29462253 Review.
Cited by
-
First-line treatment of EGFR-mutated non-small cell lung cancer with brain metastases: a systematic review and meta-analysis.Sci Rep. 2024 Oct 2;14(1):22901. doi: 10.1038/s41598-024-74496-0. Sci Rep. 2024. PMID: 39358420 Free PMC article.
-
Clinical Management of Patients with Non-Small Cell Lung Cancer, Brain Metastases, and Actionable Genomic Alterations: A Systematic Literature Review.Adv Ther. 2024 May;41(5):1815-1842. doi: 10.1007/s12325-024-02799-9. Epub 2024 Mar 21. Adv Ther. 2024. PMID: 38509433 Free PMC article. Review.
-
Bevacizumab improved prognosis for advanced EGFR-mutant lung adenocarcinoma with brain metastasis receiving cerebral radiotherapy.Clin Transl Oncol. 2024 Aug;26(8):1968-1975. doi: 10.1007/s12094-024-03418-3. Epub 2024 Mar 13. Clin Transl Oncol. 2024. PMID: 38478262 Free PMC article.
-
Comparing Efficacy of Erlotinib and Bevacizumab Combination with Erlotinib Monotherapy in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC): A Systematic Review and Meta-Analysis.Diseases. 2023 Oct 23;11(4):146. doi: 10.3390/diseases11040146. Diseases. 2023. PMID: 37873790 Free PMC article. Review.
-
A protocol of a single arm, prospective, open-label, multicenter, phase II study of ramucirumab and erlotinib in treatment-naïve non-small cell lung cancer patients with EGFR mutation and brain metastases (SPIRAL-BRAIN study).Transl Lung Cancer Res. 2023 Aug 30;12(8):1802-1806. doi: 10.21037/tlcr-23-109. Epub 2023 Aug 14. Transl Lung Cancer Res. 2023. PMID: 37691860 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous